S 237648
Alternative Names: S-237648Latest Information Update: 05 Nov 2023
At a glance
- Originator Shionogi
- Class Obesity therapies
- Mechanism of Action Neuropeptide Y5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Obesity in USA (PO)
- 28 Sep 2021 S 237648 is still in phase II trials for obesity in Japan (Shionogi pipeline, September 2021)
- 01 Feb 2019 Phase-I clinical trials in Obesity in USA (PO) before February 2019 (Shionogi pipeline, February 2019)